Published in Lancet on January 04, 1997
Hepatitis B virus biology. Microbiol Mol Biol Rev (2000) 7.58
Outcome of lamivudine resistant hepatitis B virus infection in the liver transplant recipient. Gut (2000) 2.16
The polymerase L528M mutation cooperates with nucleotide binding-site mutations, increasing hepatitis B virus replication and drug resistance. J Clin Invest (2001) 2.05
The hepatitis B virus polymerase mutation rtV173L is selected during lamivudine therapy and enhances viral replication in vitro. J Virol (2003) 1.80
Efficacy of the carbocyclic 2'-deoxyguanosine nucleoside BMS-200475 in the woodchuck model of hepatitis B virus infection. Antimicrob Agents Chemother (1998) 1.45
Two-year assessment of entecavir resistance in Lamivudine-refractory hepatitis B virus patients reveals different clinical outcomes depending on the resistance substitutions present. Antimicrob Agents Chemother (2006) 1.45
Use of real-time PCR and fluorimetry to detect lamivudine resistance-associated mutations in hepatitis B virus. Antimicrob Agents Chemother (1999) 1.41
Two sensitive PCR-based methods for detection of hepatitis B virus variants associated with reduced susceptibility to lamivudine. J Clin Microbiol (1999) 1.26
Potent efficacy of entecavir (BMS-200475) in a duck model of hepatitis B virus replication. Antimicrob Agents Chemother (2002) 1.21
Inhibition of human hepatitis B virus replication by AT-61, a phenylpropenamide derivative, alone and in combination with (-)beta-L-2',3'-dideoxy-3'-thiacytidine. Antimicrob Agents Chemother (1998) 1.21
In vitro susceptibilities of wild-type or drug-resistant hepatitis B virus to (-)-beta-D-2,6-diaminopurine dioxolane and 2'-fluoro-5-methyl-beta-L-arabinofuranosyluracil. Antimicrob Agents Chemother (2001) 1.18
In vivo antiviral activity and pharmacokinetics of (-)-cis-5-fluoro-1-[2-(hydroxymethyl)-1,3-oxathiolan-5-yl]cytosine in woodchuck hepatitis virus-infected woodchucks. Antimicrob Agents Chemother (1997) 1.14
Susceptibility of lamivudine-resistant hepatitis B virus to other reverse transcriptase inhibitors. J Clin Invest (1999) 1.10
The M539V polymerase variant of human hepatitis B virus demonstrates resistance to 2'-deoxy-3'-thiacytidine and a reduced ability to synthesize viral DNA. Antimicrob Agents Chemother (1998) 1.09
Cross-resistance testing of antihepadnaviral compounds using novel recombinant baculoviruses which encode drug-resistant strains of hepatitis B virus. Antimicrob Agents Chemother (2001) 1.09
Use of the hepatitis B virus recombinant baculovirus-HepG2 system to study the effects of (-)-beta-2',3'-dideoxy-3'-thiacytidine on replication of hepatitis B virus and accumulation of covalently closed circular DNA. Antimicrob Agents Chemother (1999) 1.05
Phenylpropenamide derivatives AT-61 and AT-130 inhibit replication of wild-type and lamivudine-resistant strains of hepatitis B virus in vitro. Antimicrob Agents Chemother (2002) 1.05
Comparison of sequence analysis and the INNO-LiPA HBV DR line probe assay for detection of lamivudine-resistant hepatitis B virus strains in patients under various clinical conditions. J Clin Microbiol (2001) 1.03
Hepatitis B virus genotypes and resistance mutations in patients under long term lamivudine therapy: characterization of genotype G in Brazil. BMC Microbiol (2008) 1.00
Hepatitis B virus (HBV) mutations associated with resistance to lamivudine in patients coinfected with HBV and human immunodeficiency virus. J Clin Microbiol (1999) 0.97
YMDD mutations in patients with chronic hepatitis B untreated with antiviral medicines. World J Gastroenterol (2005) 0.97
Inhibitory effect of 2'-fluoro-5-methyl-beta-L-arabinofuranosyl-uracil on duck hepatitis B virus replication. Antimicrob Agents Chemother (1998) 0.95
Quantitative detection of the M204V hepatitis B virus minor variants by amplification refractory mutation system real-time PCR combined with molecular beacon technology. J Clin Microbiol (2009) 0.95
Monitoring the emergence of hepatitis B virus polymerase gene variants during lamivudine therapy using the LightCycler. J Clin Microbiol (2001) 0.94
Antiviral therapies: focus on hepatitis B reverse transcriptase. Int J Biochem Cell Biol (2012) 0.89
Rebound of hepatitis B virus replication in HepG2 cells after cessation of antiviral treatment. J Virol (2002) 0.88
Improved clinical outcomes with liver transplantation for hepatitis B-induced chronic liver failure using passive immunization. Ann Surg (1998) 0.88
Outcomes of patients with hepatitis B who developed antiviral resistance while on the liver transplant waiting list. Clin Gastroenterol Hepatol (2007) 0.87
Serum hepatitis B virus DNA before liver transplantation correlates with HBV reinfection rate even under successful low-dose hepatitis B immunoglobulin prophylaxis. Hepatol Int (2011) 0.87
Which patients respond best to hepatitis B vaccination after a hepatitis B virus-related liver transplantation? J Gastroenterol (2013) 0.86
Clinical implications of lamivudine resistance by HBV. Lancet (1997) 0.85
Molecular diagnosis of entecavir resistance. Hepat Mon (2010) 0.84
Current and future antiviral drug therapies of hepatitis B chronic infection. World J Hepatol (2015) 0.83
Molecular epidemical characteristics of Lamivudine resistance mutations of HBV in southern China. Med Sci Monit (2011) 0.83
Novel mutation in YMDD motif and direct neighbourhood in a child with chronic HBV-infection and clinical lamivudine and adefovir resistance - a scholarly case. Virol J (2010) 0.82
Hepatitis B surface antigen variant with multiple mutations in the a determinant in an agammaglobulinemic patient. J Clin Microbiol (2004) 0.81
Early detection and quantification of lamivudine-resistant hepatitis B virus mutants by fluorescent biprobe hybridization assay in lamivudine-treated patients. J Gastroenterol (2006) 0.81
Novel nucleoside analogue MCC-478 (LY582563) is effective against wild-type or lamivudine-resistant hepatitis B virus. Antimicrob Agents Chemother (2002) 0.81
Changes in the antigenicity of a hepatitis B virus mutant stemming from lamivudine therapy. Antimicrob Agents Chemother (2000) 0.80
Hepatitis B virus variants in an HIV-HBV co-infected patient at different periods of antiretroviral treatment with and without lamivudine. BMC Infect Dis (2004) 0.79
In vitro study of the effects of precore and lamivudine-resistant mutations on hepatitis B virus replication. J Virol (2007) 0.78
Evaluation of single and combination therapies with tenofovir disoproxil fumarate and emtricitabine in vitro and in a robust mouse model supporting high levels of hepatitis B virus replication. Antimicrob Agents Chemother (2012) 0.78
Multicenter studies of Lamivudine for the treatment and prevention of hepatitis B after liver transplantation. Ochsner J (1999) 0.77
trans-Complementation of HBV rtM204I mutant replication by HBV wild-type polymerase. Virology (2009) 0.75
Direct acting antivirals for the treatment of chronic viral hepatitis. Scientifica (Cairo) (2012) 0.75
Establishment of drug-resistant HBV small-animal models by hydrodynamic injection. Acta Pharm Sin B (2014) 0.75
Clinical features of chronic hepatitis B patients with YMDD mutation after lamivudine therapy. J Zhejiang Univ Sci B (2005) 0.75
Long term outcome of liver transplantation for viral hepatitis: is there a need to re-evaluate patient selection? Gut (1999) 0.75
Update in internal medicine. Arch Med Res (2000) 0.75
Long-term effects of prophylactic and therapeutic lamivudine treatments in hepatitis B surface antigen-positive renal allograft recipients. Clin Exp Nephrol (2013) 0.75
Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. Hepatitis Interventional Therapy Group. N Engl J Med (1998) 14.40
Spirometric standards for healthy nonsmoking adults. Am Rev Respir Dis (1971) 9.69
Infections after liver transplantation. An analysis of 101 consecutive cases. Medicine (Baltimore) (1988) 5.77
Lamivudine as initial treatment for chronic hepatitis B in the United States. N Engl J Med (1999) 5.32
Intestinal transplantation in composite visceral grafts or alone. Ann Surg (1992) 4.96
A preliminary trial of lamivudine for chronic hepatitis B infection. N Engl J Med (1995) 4.84
Treatment of chronic hepatitis C with recombinant interferon alfa. A multicenter randomized, controlled trial. Hepatitis Interventional Therapy Group. N Engl J Med (1989) 4.69
A randomized, controlled trial of interferon alfa-2b alone and after prednisone withdrawal for the treatment of chronic hepatitis B. The Hepatitis Interventional Therapy Group. N Engl J Med (1990) 4.53
The arterial pole of the mouse heart forms from Fgf10-expressing cells in pharyngeal mesoderm. Dev Cell (2001) 4.27
Identification and characterization of mutations in hepatitis B virus resistant to lamivudine. Lamivudine Clinical Investigation Group. Hepatology (1998) 4.14
Clinical presentation of hepatic artery thrombosis after liver transplantation in the cyclosporine era. Transplantation (1985) 3.91
Hepatic resection versus transplantation for hepatocellular carcinoma. Ann Surg (1991) 3.57
Hepatitis C virus genotypes in the United States: epidemiology, pathogenicity, and response to interferon therapy. Collaborative Study Group. Ann Intern Med (1996) 3.38
A randomized, double-blind trial comparing pegylated interferon alfa-2b to interferon alfa-2b as initial treatment for chronic hepatitis C. Hepatology (2001) 3.02
Review article: herbal and dietary supplement hepatotoxicity. Aliment Pharmacol Ther (2012) 2.89
Experience in 1,000 liver transplants under cyclosporine-steroid therapy: a survival report. Transplant Proc (1988) 2.87
The 5' nontranslated region of hepatitis A virus RNA: secondary structure and elements required for translation in vitro. J Virol (1991) 2.83
Etiology and outcome for 295 patients with acute liver failure in the United States. Liver Transpl Surg (1999) 2.79
Cadaveric small bowel and small bowel-liver transplantation in humans. Transplantation (1992) 2.75
Genetic relatedness of hepatitis A virus strains recovered from different geographical regions. J Gen Virol (1992) 2.74
Extended lamivudine treatment in patients with chronic hepatitis B enhances hepatitis B e antigen seroconversion rates: results after 3 years of therapy. Hepatology (2001) 2.72
The role of liver transplantation in hepatobiliary malignancy. A retrospective analysis of 95 patients with particular regard to tumor stage and recurrence. Ann Surg (1989) 2.71
Extended lamivudine retreatment for chronic hepatitis B: maintenance of viral suppression after discontinuation of therapy. Hepatology (1999) 2.64
Long-term therapy of chronic hepatitis B with lamivudine. Hepatology (2000) 2.49
Pneumocystis carinii hepatitis in the acquired immunodeficiency syndrome (AIDS) Ann Intern Med (1989) 2.42
Antigenic and genetic variation in cytopathic hepatitis A virus variants arising during persistent infection: evidence for genetic recombination. J Virol (1991) 2.36
Type B hepatitis after needle-stick exposure: prevention with hepatitis B immune globulin. Final report of the Veterans Administration Cooperative Study. Ann Intern Med (1978) 2.29
Cholangiocarcinoma in patients with primary sclerosing cholangitis: a multicenter case-control study. Hepatology (2000) 2.21
Formation of the atrioventricular septal structures in the normal mouse. Circ Res (1998) 2.21
Human islet isolation and allotransplantation in 22 consecutive cases. Transplantation (1992) 2.20
Pathological diagnosis of chronic hepatitis C: a multicenter comparative study with chronic hepatitis B. The Hepatitis Interventional Therapy Group. Gastroenterology (1993) 2.20
Vegetative infection of transjugular intrahepatic portosystemic shunts. Gastroenterology (1998) 2.20
Indeterminate hepatitis C. Lancet (1993) 2.17
Human growth hormone release: relation to slow-wave sleep and sleep-walking cycles. Science (1969) 2.15
Failure of Centers for Disease Control criteria to identify hepatitis B infection in a large municipal obstetrical population. Ann Intern Med (1987) 2.14
Long-term mortality and morbidity of transfusion-associated non-A, non-B, and type C hepatitis: A National Heart, Lung, and Blood Institute collaborative study. Hepatology (2001) 2.13
Complications of venous reconstruction in human orthotopic liver transplantation. Ann Surg (1987) 2.11
Hepatitis C-associated hepatocellular carcinoma. Hepatology (1990) 2.07
Measurement of serum hyaluronic acid in patients with chronic hepatitis C and its relationship to liver histology. Consensus Interferon Study Group. J Gastroenterol Hepatol (2000) 2.06
Clinical relevance of hepatitis B viral mutations. Hepatology (2000) 2.03
[Transplantation of a donor liver to 2 recipients (splitting transplantation)--a new method in the further development of segmental liver transplantation]. Langenbecks Arch Chir (1988) 2.02
Sedative-hypnotics and human performance. Psychopharmacology (Berl) (1982) 2.00
Characterization of the kinetics of the passive and active transport mechanisms for bile acid absorption in the small intestine and colon of the rat. J Clin Invest (1972) 2.00
Effects of slow wave sleep deprivation on human growth hormone release in sleep: preliminary study. Life Sci (1969) 2.00
FK 506 in steroid-resistant focal sclerosing glomerulonephritis of childhood. Lancet (1990) 1.94
Analysis of donor criteria for the prediction of outcome in clinical liver transplantation. Transplant Proc (1987) 1.90
The role of laparoscopy in the diagnosis of cirrhosis. Gastrointest Endosc (1996) 1.89
The Oxford Clinical Cataract Classification and Grading System. Int Ophthalmol (1986) 1.87
The adverse impact on liver transplantation of using positive cytotoxic crossmatch donors. Transplantation (1992) 1.83
Large cystic lesions of the liver in adults: a 15-year experience in a tertiary center. J Am Coll Surg (2001) 1.79
Regulation of left-right asymmetry by thresholds of Pitx2c activity. Development (2001) 1.77
Hepatic artery in liver transplantation. Transplant Proc (1987) 1.73
Benign and solid tumors of the liver: relationship to sex, age, size of tumors, and outcome. Am Surg (2001) 1.72
Evaluation of monovalent influenza vaccine in a retirement community during the epidemic of 1965-66. JAMA (1969) 1.67
Impact of virologic breakthrough and HBIG regimen on hepatitis B recurrence after liver transplantation. Am J Transplant (2010) 1.67
Hepatic artery thrombosis after pediatric liver transplantation--a medical or surgical event? Transplantation (1989) 1.67
Waves of mouse Lunatic fringe expression, in four-hour cycles at two-hour intervals, precede somite boundary formation. Curr Biol (1998) 1.65
Role of viral load in heterosexual transmission of human immunodeficiency virus type 1 by blood transfusion recipients. Transfusion Safety Study Group. Am J Epidemiol (1997) 1.62
A serologic follow-up of the 1942 epidemic of post-vaccination hepatitis in the United States Army. N Engl J Med (1987) 1.61
Clinical and serological features of human herpesvirus-6 infection in three adults. Lancet (1988) 1.61
Liver transplantation: an unfinished product. Transplant Proc (1989) 1.61
Efficacy of hepatitis B immune serum globulin after accidental exposure. Preliminary report of the Veterans Administration Cooperative Study. Lancet (1975) 1.59
The spectrum of portal vein thrombosis in liver transplantation. Ann Surg (1991) 1.58
Comparison of FK-506 and cyclosporine regimens in pediatric renal transplantation. Pediatr Nephrol (1994) 1.55
Lamivudine treatment for decompensated cirrhosis resulting from chronic hepatitis B. Hepatology (2000) 1.55
Lamivudine therapy of WHV-infected woodchucks. Virology (1998) 1.52
Cell-mediated hepatic injury in alcoholic liver disease. Veterans Affairs Cooperative Study Group 275. Gastroenterology (1993) 1.52
Hepatic iron concentration as a predictor of response to interferon alfa therapy in chronic hepatitis C. Gastroenterology (1995) 1.51
The comparative survivals of alcoholics versus nonalcoholics after distal splenorenal shunt. Ann Surg (1978) 1.49
Hepatitis C infection by polymerase chain reaction in alcoholics: false-positive ELISA results and the influence of infection on a clinical prognostic score. Am J Gastroenterol (1993) 1.48
A multicenter study of lamivudine treatment in 33 patients with hepatitis B after liver transplantation. Liver Transpl (2001) 1.47
Iridotomy with a ruby laser. Br J Ophthalmol (1973) 1.47
Biometry of the crystalline lens in early-onset diabetes. Br J Ophthalmol (1990) 1.47
Atrial development in the human heart: an immunohistochemical study with emphasis on the role of mesenchymal tissues. Anat Rec (2000) 1.46
Microsporidan hepatitis in the acquired immunodeficiency syndrome. Ann Intern Med (1987) 1.45
Orthotopic liver transplantation for alcoholic cirrhosis. JAMA (1988) 1.45
The influence of low-, normal-, and high-carbohydrate meals on blood pressure in elderly patients with postprandial hypotension. J Gerontol A Biol Sci Med Sci (2001) 1.45
Gram-negative sepsis in neonates: a nursery outbreak due to hand carriage of Citrobacter diversus. Pediatrics (1980) 1.44
Laparoscopic evaluation of liver disease in chronic renal failure prior to renal transplantation. Gastrointest Endosc (1997) 1.42
Cataract: the relation between myopia and cataract morphology. Br J Ophthalmol (1987) 1.42
Haemoglobin catabolism: the role of ferrihaems in studies of the degradation pathway. Biochem J (1974) 1.41
Small bowel transplantation--a clinical review. Am J Gastroenterol (1999) 1.40
[Cholinesterase inhibitors in Alzheimer disease: preliminary recommendations for treatment]. Ned Tijdschr Geneeskd (1998) 1.40
Use of diuretics and opportunities for withdrawal in a Dutch nursing home population. Neth J Med (1998) 1.39